- Report
- March 2025
- 145 Pages
Global
From €4040EUR$4,365USD£3,398GBP
€4489EUR$4,850USD£3,775GBP
- Report
- August 2020
- 250 Pages
Saudi Arabia
From €3332EUR$3,600USD£2,802GBP
- Report
- July 2024
- 70 Pages
Brazil
From €4396EUR$4,750USD£3,697GBP
- Report
- February 2024
- 150 Pages
Global
From €4396EUR$4,750USD£3,697GBP
- Report
- February 2024
- 70 Pages
South Africa
From €4396EUR$4,750USD£3,697GBP
- Report
- February 2024
- 70 Pages
Indonesia
From €4396EUR$4,750USD£3,697GBP
- Report
- February 2024
- 70 Pages
Philippines
From €4396EUR$4,750USD£3,697GBP
- Report
- February 2024
- 70 Pages
India
From €4396EUR$4,750USD£3,697GBP
- Report
- February 2024
- 70 Pages
New Zealand
From €4396EUR$4,750USD£3,697GBP
- Report
- February 2024
- 90 Pages
Asia Pacific
From €4396EUR$4,750USD£3,697GBP
- Report
- February 2024
- 80 Pages
Latin America
From €4396EUR$4,750USD£3,697GBP
- Report
- February 2024
- 80 Pages
Europe
From €4396EUR$4,750USD£3,697GBP
- Report
- February 2024
- 150 Pages
Global
From €4396EUR$4,750USD£3,697GBP
- Report
- February 2024
- 70 Pages
Japan
From €4396EUR$4,750USD£3,697GBP
- Report
- February 2024
- 70 Pages
Italy
From €4396EUR$4,750USD£3,697GBP
- Report
- February 2024
- 70 Pages
India
From €4396EUR$4,750USD£3,697GBP
- Report
- February 2024
- 70 Pages
New Zealand
From €4396EUR$4,750USD£3,697GBP
- Report
- February 2024
- 70 Pages
North America
From €4396EUR$4,750USD£3,697GBP
- Report
- February 2024
- 70 Pages
Europe
From €4396EUR$4,750USD£3,697GBP
- Report
- February 2024
- 70 Pages
Asia Pacific
From €4396EUR$4,750USD£3,697GBP

Vildagliptin is a drug used to treat endocrine and metabolic disorders. It is a dipeptidyl peptidase-4 (DPP-4) inhibitor, which works by increasing the amount of incretin hormones in the body. This helps to reduce blood sugar levels in people with type 2 diabetes. Vildagliptin is usually taken in combination with other diabetes medications, such as metformin or a sulfonylurea. It is also used to treat non-alcoholic fatty liver disease (NAFLD).
Vildagliptin is available in tablet form and is taken orally. It is generally well tolerated, with the most common side effects being nausea, diarrhea, and headache. It is important to note that vildagliptin can interact with other medications, so it is important to discuss all medications with a healthcare provider before taking vildagliptin.
Vildagliptin is marketed by several companies, including Novartis, Merck, and Boehringer Ingelheim. It is also available in generic form from several generic drug manufacturers. Show Less Read more